Report Detail
Global Oncology Drugs Market Insights, Forecast to 2025
- RnM2398324 |
- 25 March, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others.
Oncology Drugs is widely used For Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer and Other Cancer Treatment. The most proportion of Oncology Drugs used for Blood Cancer and the proportion in 2017 is 22.74%.
The global Oncology Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oncology Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Oncology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oncology Drugs in these regions.
This research report categorizes the global Oncology Drugs market by top players/brands, region, type and end user. This report also studies the global Oncology Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
HENGRUI
AstraZeneca
QILU
Sanofi
HANSOH
LUYE
Novartis
GuiZhou YiBai
Lunan
Eli Lilly and Company
Market size by Product
Antimetabolite
Alkaloid drugs
Hormone
Targeted drug
Platinum-based drugs
Other
Market size by End User
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Oncology Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Oncology Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Oncology Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Oncology Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Oncology Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (BBL). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Oncology Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Oncology Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Oncology Drugs Market Size Growth Rate by Product
- 1.4.2 Antimetabolite
- 1.4.3 Alkaloid drugs
- 1.4.4 Hormone
- 1.4.5 Targeted drug
- 1.4.6 Platinum-based drugs
- 1.4.7 Other
- 1.5 Market by End User
- 1.5.1 Global Oncology Drugs Market Size Growth Rate by End User
- 1.5.2 Blood Cancer
- 1.5.3 Breast Cancer
- 1.5.4 Gastrointestinal Cancer
- 1.5.5 Prostate Cancer
- 1.5.6 Respiratory/Lung Cancer
- 1.5.7 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Oncology Drugs Market Size
- 2.1.1 Global Oncology Drugs Revenue 2014-2025
- 2.1.2 Global Oncology Drugs Sales 2014-2025
- 2.2 Oncology Drugs Growth Rate by Regions
- 2.2.1 Global Oncology Drugs Sales by Regions
- 2.2.2 Global Oncology Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Oncology Drugs Sales by Manufacturers
- 3.1.1 Oncology Drugs Sales by Manufacturers
- 3.1.2 Oncology Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Oncology Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Oncology Drugs Revenue by Manufacturers
- 3.2.1 Oncology Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Oncology Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Oncology Drugs Price by Manufacturers
- 3.4 Oncology Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Oncology Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Oncology Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Oncology Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Oncology Drugs Sales by Product
- 4.2 Global Oncology Drugs Revenue by Product
- 4.3 Oncology Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Oncology Drugs Breakdown Data by End User
6 North America
- 6.1 North America Oncology Drugs by Countries
- 6.1.1 North America Oncology Drugs Sales by Countries
- 6.1.2 North America Oncology Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Oncology Drugs by Product
- 6.3 North America Oncology Drugs by End User
7 Europe
- 7.1 Europe Oncology Drugs by Countries
- 7.1.1 Europe Oncology Drugs Sales by Countries
- 7.1.2 Europe Oncology Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Oncology Drugs by Product
- 7.3 Europe Oncology Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Oncology Drugs by Countries
- 8.1.1 Asia Pacific Oncology Drugs Sales by Countries
- 8.1.2 Asia Pacific Oncology Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Oncology Drugs by Product
- 8.3 Asia Pacific Oncology Drugs by End User
9 Central & South America
- 9.1 Central & South America Oncology Drugs by Countries
- 9.1.1 Central & South America Oncology Drugs Sales by Countries
- 9.1.2 Central & South America Oncology Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Oncology Drugs by Product
- 9.3 Central & South America Oncology Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Oncology Drugs by Countries
- 10.1.1 Middle East and Africa Oncology Drugs Sales by Countries
- 10.1.2 Middle East and Africa Oncology Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Oncology Drugs by Product
- 10.3 Middle East and Africa Oncology Drugs by End User
11 Company Profiles
- 11.1 Roche
- 11.1.1 Roche Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Roche Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Roche Oncology Drugs Products Offered
- 11.1.5 Roche Recent Development
- 11.2 HENGRUI
- 11.2.1 HENGRUI Company Details
- 11.2.2 Company Business Overview
- 11.2.3 HENGRUI Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 HENGRUI Oncology Drugs Products Offered
- 11.2.5 HENGRUI Recent Development
- 11.3 AstraZeneca
- 11.3.1 AstraZeneca Company Details
- 11.3.2 Company Business Overview
- 11.3.3 AstraZeneca Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 AstraZeneca Oncology Drugs Products Offered
- 11.3.5 AstraZeneca Recent Development
- 11.4 QILU
- 11.4.1 QILU Company Details
- 11.4.2 Company Business Overview
- 11.4.3 QILU Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 QILU Oncology Drugs Products Offered
- 11.4.5 QILU Recent Development
- 11.5 Sanofi
- 11.5.1 Sanofi Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Sanofi Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Sanofi Oncology Drugs Products Offered
- 11.5.5 Sanofi Recent Development
- 11.6 HANSOH
- 11.6.1 HANSOH Company Details
- 11.6.2 Company Business Overview
- 11.6.3 HANSOH Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 HANSOH Oncology Drugs Products Offered
- 11.6.5 HANSOH Recent Development
- 11.7 LUYE
- 11.7.1 LUYE Company Details
- 11.7.2 Company Business Overview
- 11.7.3 LUYE Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 LUYE Oncology Drugs Products Offered
- 11.7.5 LUYE Recent Development
- 11.8 Novartis
- 11.8.1 Novartis Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Novartis Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Novartis Oncology Drugs Products Offered
- 11.8.5 Novartis Recent Development
- 11.9 GuiZhou YiBai
- 11.9.1 GuiZhou YiBai Company Details
- 11.9.2 Company Business Overview
- 11.9.3 GuiZhou YiBai Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 GuiZhou YiBai Oncology Drugs Products Offered
- 11.9.5 GuiZhou YiBai Recent Development
- 11.10 Lunan
- 11.10.1 Lunan Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Lunan Oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Lunan Oncology Drugs Products Offered
- 11.10.5 Lunan Recent Development
- 11.11 Eli Lilly and Company
12 Future Forecast
- 12.1 Oncology Drugs Market Forecast by Regions
- 12.1.1 Global Oncology Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Oncology Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Oncology Drugs Market Forecast by Product
- 12.2.1 Global Oncology Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Oncology Drugs Revenue Forecast by Product 2019-2025
- 12.3 Oncology Drugs Market Forecast by End User
- 12.4 North America Oncology Drugs Forecast
- 12.5 Europe Oncology Drugs Forecast
- 12.6 Asia Pacific Oncology Drugs Forecast
- 12.7 Central & South America Oncology Drugs Forecast
- 12.8 Middle East and Africa Oncology Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Oncology Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Oncology Drugs . Industry analysis & Market Report on Oncology Drugs is a syndicated market report, published as Global Oncology Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Oncology Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
